Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing

Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing

Abstract Low-grade serous ovarian cancer (LGSOC) typically responds poorly to standard platinum-based chemotherapy and new therapeutic approaches are needed. We describe a remarkable response to targeted therapy in a patient with platinum-resistant, advanced LGSOC who had failed standard-of-care che...

Full description

Bibliographic Details
Main Authors: Heidi J. Gray, Payel Chatterjee, Rachele Rosati, Lauren R. Appleyard, Grace J. Durenberger, Robert L. Diaz, Hallie A. Swan, Danielle Peretti, Maddy Pollastro, Trevor Ainge, Katannya Kapeli, Shalini Pereira, Astrid L. Margossian, Kalyan Banda, Barbara A. Goff, Elizabeth M. Swisher, Brady Bernard, Christopher J. Kemp, Carla Grandori
Format: Article
Language:English
Published: Nature Portfolio 2023-05-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-023-00379-8

Internet

https://doi.org/10.1038/s41698-023-00379-8

Similar Items